Brand new ophthalmic product packaging
Brentwood, 21 September 2011: Martindale Pharma®, leaders in the manufacture and supply of specialty pharmaceuticals and services, announces that starting in October, its ophthalmic range of products will start appearing on pharmacists shelves in brand new eye-catching, colour-coded and easy-to-read packaging.
“It’s all about clarity.” Says Richard de Souza, Chief Executive Officer. “This clean, consistent new look being rolled out across our entire ophthalmic product range will help make it easier for pharmacists and medical professionals to recognise the exact medicine and dosage they need at a glance.”
The first of the products to feature the redesigned packaging will be another addition to the Martindale Pharma ophthalmic range, Atropine Eye Drops 0.5% w/v 10ml, which will be available through wholesalers during October 2011. The exciting new livery will start to appear across the range over the coming months with Chloramphenicol Eye Drops 0.5% w/v 10ml and Hypromellose Eye Drops 0.3% w/v 10ml being made available in this new style during October. Pip codes remain unchanged;
- Atropine Eye Drops 0.5% w/v 10ml – Pip code 105-7611
- Chloramphenicol Eye Drops 0.5% w/v 10ml – Pip code 105-7629
- Hypromellose Eye Drops 0.3% w/v 10ml – Pip code 105-7686
This initiative is part of a wider, ongoing drive by Martindale Pharma® to modernise and revitalise all of their product packaging.
For further information or support, you can contact Martindale Pharma® on 0800 028 7933 or email connect@martindalepharma.co.uk
Notes to editors:
After starting out as a London chemist store owned by William Martindale, Martindale Pharma has remained in business for more than a century and is now firmly established as a leading supplier to the UK’s NHS and exports its products to a number of other major pharmaceutical markets.
In May 2010 AAC Capital bought Martindale Pharma from Cardinal Health. AAC Capital continues to develop the business and pursue growth opportunities.
Martindale Pharma manufacture the majority of their product‟s at their own facilities in the UK, in total producing and packing c.50 million doses a year in a range of formats including sterile ampoules/vials, oral solutions, pre-filled syringes, suppositories and ophthalmics.
Martindale Pharma’s key business segments are:
For further information visit martindalepharma.co.uk
Media contacts:
Martindale Pharma
Michael Clark
Tel: +44 (0) 1277 235313
M:Communications
Mary Clark / Amber Bielecka
Tel : +44 (0) 207 920 2361